גברטו - Gavreto
×ת×ר××: 31/10/2024 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ק×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01EX Other protein kinase inhibitors | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||||||||||
| צ×רת ××ª× | פ××× - PER OS | |||||||||||||
| צ×רת ××× ×× | קפס××× ×§×©×××, CAPSULE, HARD ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||||||||||
| ×ת×××× | - GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).- GAVRETO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.- GAVRETO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). | |||||||||||||
| ||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 ××× ×¢××× ×ר××¤× Â | |||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××ר×× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | F. HOFFMANN-LA ROCHE AG, SWITZERLAND |
| ×©× ××¢× ×ר×ש×× | ROCHE PHARMACEUTICALS (ISRAEL) LTD |
| ר×ש××× | ת×ר×× ××ש×: 4/2021. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 31/10/2024 |
השינוי האחרון נעשה בֹ־16 בספטמבר 2025 ב־06:10